載入中
NASDAQHealthcareBiotechnology
最新資料
US$7.055
+US$0.235 · +3.45%
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
前收盤價
US$7.055
+US$0.235 · +3.45%
盤中時間採用ET。市場資料可能有所延遲。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日內區間
目前US$7.055
52週區間
目前US$7.055
盤中時間採用ET。市場資料可能有所延遲。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日內區間
目前US$7.055
52週區間
目前US$7.055
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 279.7萬 USD | 3891.3萬 USD | 2600.4萬 USD | 1.11億 USD | 8507.7萬 USD |
| 銷貨成本 | — | — | — | 203.7萬 USD | — |
| 毛利 | 279.7萬 USD | 3891.3萬 USD | 2600.4萬 USD | 1.09億 USD | 8507.7萬 USD |
| 研究與開發 | 5803.4萬 USD | 4510.5萬 USD | 7126萬 USD | 7237.7萬 USD | 6873.6萬 USD |
| 銷售、一般及管理費用 | 3146.8萬 USD | 3012.6萬 USD | 4045萬 USD | 2386.2萬 USD | 2093.8萬 USD |
| 營業費用 | 8950.2萬 USD | 8281萬 USD | 1.12億 USD | 9420.2萬 USD | 8967.4萬 USD |
| 利息收入 | 657.9萬 USD | 738.6萬 USD | 496.4萬 USD | — | — |
| 利息支出 | — | — | 283.3萬 USD | 303.1萬 USD | 284.4萬 USD |
| 折舊和攤銷 | 295.9萬 USD | 115.1萬 USD | 84.3萬 USD | 128.7萬 USD | 125.2萬 USD |
| 營業利益 | −8670.5萬 USD | −4389.7萬 USD | −8641.6萬 USD | 1453.8萬 USD | −459.7萬 USD |
| 淨利 | −1.3億 USD | −7742.4萬 USD | −2.2億 USD | 3537.9萬 USD | −2568.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI349.21萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM235.96萬0.00%787.4億 USD0.19%US$278.94+0.49%
Janus Henderson Small Cap Growth Alpha ETFJSML158.07萬0.44%3.61億 USD0.30%US$87.477+1.00%
Vanguard Extended Market ETFVXF157.51萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC28.51萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM18萬0.15%1.17億 USD0.73%US$15.9402+0.25%
iShares Russell 2000 Growth ETFIWO11.59萬0.00%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 Value ETFVTWV10.16萬0.01%14億 USD0.06%US$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMJanus Henderson Small Cap Growth Alpha ETFJSMLVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
